Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 76, Issue 3, 2010, Pages 371-375

  Zhang, Yu Hui ^a   Yue, Zhi Jian ^a   Zhang, He ^a   Tang, Gu Sheng ^a   Wang, Yang ^a   Liu, Jian Min ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Glioma; Interstitial chemotherapy; Temozolomide

Indexed keywords

POLYGLACTIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VATALANIB; ZK 212583;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GLIOMA; MALE; NONHUMAN; RAT; SURVIVAL TIME;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; LACTIC ACID; MALE; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; POLYGLYCOLIC ACID; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 78549284859     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.08.011     Document Type: Article

References (30)

1. Zhang H., Gao S. Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int. J. Pharm. 2007, 329:122-128.
2. Conrad C., Friedman H., Reardon D., Provenzale J., Jackson E., Serajuddin H., Laurent D., Chen B., Yung W.K.A. A phase I/II trial of a single agent PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Am. Soc. Clin. Oncol. Annu. Meet. 2004, 22:1512.
3. Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001, 15:1311-1333.
4. Colman H., Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Arch. Neurol. 2008, 65:877-883.
5. Benitez J.A., Dominguez-Monzon G., Segovia J. Conventional and gene therapy strategies for the treatment of brain tumors. Curr. Med. Chem. 2008, 15:729-742.
6. Fine H.A., Dear K.B., Loeffler J.S., Black P.M., Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
7. Attenello F.J., Mukherjee D., Datoo G., McGirt M.J., Bohan E., Weingart J.D., Olivi A., Quinones-Hinojosa A., Brem H. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann. Surg. Oncol. 2008, 15:2887-2893.
8. Wen P.Y., Kesari S. Malignant gliomas in adults. New Engl. J. Med. 2008, 359:492-507.
9. Combs S.E., Wagner J., Bischof M., Welzel T., Edler L., Rausch R., Wagner F., Zabel-du Bois A., Debus J., Schulz-Ertner D. Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int. J. Radiat. Oncol. Biol. Phys. 2008, 71:999-1005.
10. Brandes A.A. State-of-the-art treatment of high-grade brain tumors. Semin. Oncol. 2003, 30:4-9.
11. Zawlik I., Vaccarella S., Kita D., Mittelbronn M., Franceschi S., Ohgaki H. Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology 2009, 32:21-29.
12. Wu J.Y., Wang J., Lai J.C., Cheng Y.W., Yeh K.T., Wu T.C., Chen C.Y., Lee H. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status. Ann. Surg. Oncol. 2008, 15:3272-3277.
13. Chang S.M., Lamborn K.R., Malec M., Larson D., Wara W., Sneed P., Rabbitt J., Page M., Nicholas M.K., Prados M.D. Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys. 2004, 60:353-357.
14. Brem H., Piantadosi S., Burger P.C., Walker M., Selker R., Vick N.A., Black K., Sisti M., Brem S., Mohr G., Muller P., Morawetz R., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995, 345:1008-1012.
15. Fine H.A., Wen P.Y., Maher E.A., Viscosi E., Batchelor T., Lakhani N., Figg W.D., Purow B.W., Borkowf C.B. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J. Clin. Oncol. 2003, 21:2299-2304.
16. Goldbrunner R.H., Bendszus M., Wood J., Kiderlen M., Sasaki M., Tonn J.C. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004, 55:426-432.
17. Sathornsumetee S., Rich J.N. Antiangiogenic therapy in malignant glioma: promise and challenge. Curr. Pharm. Des. 2007, 13:3545-3558.
18. Drevs J., Muller-Driver R., Wittig C., Fuxius S., Esser N., Hugenschmidt H., Konerding M.A., Allegrini P.R., Wood J., Hennig J., Unger C., Marme D. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 2002, 4015-4022.
19. Hess C., Vuong V., Hegyi I., Riesterer O., Wood J., Fabbro D., Glanzmann C., Bodis S., Pruschy M. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br. J. Cancer 2001, 85:2010-2016.
20. Plate K.H., Breier G., Weich H.A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359:845-848.
21. Norden A.D., Drappatz J., Wen P.Y. Novel anti-angiogenic therapies for malignant gliomas. Lancet Neurol. 2008, 7:1152-1160.
22. Chi A., Norden A.D., Wen P.Y. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther. 2007, 7:1537-1560.
23. Mauceri H.J., Hanna N.N., Beckett M.A., Gorski D.H., Staba M.J., Stellato K.A., Bigelow K., Heimann R., Gately S., Dhanabal M., Soff G.A., Sukhatme V.P., et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998, 394:287-291.
24. Reardon D., Friedman H., Brada N., Conrad C., Provenzale J., Jackson E., Serajuddin H., Chen B. A phase I/II trial of PTK787/ZK 222584 (PTK/ZK), a multi-VEGF receptor tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme (GBM). Neuro-oncology 2004, 6:381.
25. Ziobro M., Rolski J., Grela-Wojewoda A., Zygulska A., Niemiec M. Effects of palliative treatment with temozolomide in patients with high-grade gliomas. Neurol. Neurochir. Pol. 2008, 42:210-215.
26. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New Engl. J. Med. 2005, 352:997-1003.
27. Kang S.G., Kim J.S., Park K., Kim J.S., Groves M.D., Nam D.H. Combination celecoxib and temozolomide in C6 rat glioma orthotopic model. Oncol. Rep. 2009, 15:7-13.
28. Devineni D., Klein-Szanto A., Gallo J.M. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res. 1996, 56:1983-1987.
29. Kim J.T., Kim J.S., Ko K.W., Kong D.S., Kang C.M., Kim M.H., Son M.J., Song H.S., Shin H.J., Lee D.S., Eoh W., Nam D.H. Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol. Rep. 2006, 16:33-39.
30. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.